Nodality applies Single Cell Network Profiling (SCNP) in two, distinct ways:
- Drug development: drug profiling tools to compare drug candidates, reveal mechanism of action, determine PK/PD relationships, identify optimal drug combinations, and select patient responders
- Clinical medicine: the development of highly predictive clinical tests that better link individual disease biology to effective treatments
Drug Development
Nodality's primary focus is to partner with pharmaceutical and biotechnology companies to improve the development and commercialization of novel therapeutics in oncology and autoimmune diseases. A growing body of evidence suggests that drug and target interactions occur within a complex and intricate network of biological effects, and therefore a network, or systems biology, approach to the study of human disease and drug-therapy interactions is critical to improving the efficiency of drug development.
Nodality has demonstrated that SCNP has application in the discovery and development of new therapeutics in areas including:
- Preclinical
- MOA profiling
- Lead selection
- Clinical
- Dose/schedule optimization
- Patient selection, including a priori selection prior to clinical efficacy studies
- Disease monitoring
- Commercial
- Patient selection (e.g. companion diagnostics)
- Resistance characterization
Clinical Diagnostics
SCNP can be used to develop and commercialize clinical tests which can enhance clinical decisions and improve therapeutic efficacy and efficiency. These tests can be companion diagnostics developed during the drug development process which can increase the likelihood of success in regulatory approval, reimbursement and commercialization. These tests can also be standalone tests such as predictive tests that indicate which patients will respond to therapy and inform treatment decisions. To this end, Nodality has validated a novel predictor of response to induction chemotherapy in pediatric Acute Myeloid Leukemia (AML) and is extending the tests in separate validation studies in elderly adult and young adult patients with AML. The pediatric AML induction therapy response test is the first clinically validated SCNP assay and supports further exploration of SCNP for both predictive and prognostic tests in AML and other diseases.